S Considine1, R Heaney2, R Conroy3, J A Thornhill2. 1. Department of Urology, Tallaght Hosptial, Dublin 24, Ireland. s.w.considine@gmail.com. 2. Department of Urology, Tallaght Hosptial, Dublin 24, Ireland. 3. Department of Epidemiology and Public Health Medicine, Royal College of Surgeons in Ireland, Dublin 2, Ireland.
Abstract
INTRODUCTION: Post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) is an important tool in the management of advanced germ cell testis cancer, particularly non-seminoma. AIM: We present the 16-year experience with PC-RPLND in a single Irish tertiary referral centre, and compare our results to the major speciality centres worldwide. METHODOLOGY: All 78 patients undergoing PC-RPLND for the treatment of metastatic testis cancer between January 1996 and December 2011 were included. Medical records were reviewed and up to date follow-up obtained from primary referral centres, patient's GPs and individual patient interview. RESULTS: The mean age at diagnosis was 28.5 ± 7 years. Initial pathology included non-seminoma 62.8 %, seminoma 6.4 % and combined 19.2 %. All patients underwent pre-operative chemotherapy. The resection template utilised was bilateral infra-hilar in 29.5 %, unilateral infra-hilar in 46.2 % and supra-hilar in 20.5 %. Complete abdominal remission was achieved in all but one patient. Additional procedures were required in 38.5 % of patients (n = 30). Clavien Dindo grade three or four complications were seen in 8.9 %, including five patients who required early reoperation. Histology of RPLND specimen showed mature teratoma (41 %) and active cancer (11.5 %). Follow-up data were available for 66 patients (85 %). Median follow-up was 101 (11-207) months. Nine patients relapsed with median time to relapse 15 (8-60) months. Overall 5-year survival rate was 95.2 % (four deaths). CONCLUSION: In this relatively small series due to small population and low disease incidence, we have shown acceptable peri-operative course, morbidity and oncological outcomes with PC-RPLND compared to major international centres.
INTRODUCTION: Post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) is an important tool in the management of advanced germ cell testis cancer, particularly non-seminoma. AIM: We present the 16-year experience with PC-RPLND in a single Irish tertiary referral centre, and compare our results to the major speciality centres worldwide. METHODOLOGY: All 78 patients undergoing PC-RPLND for the treatment of metastatic testis cancer between January 1996 and December 2011 were included. Medical records were reviewed and up to date follow-up obtained from primary referral centres, patient's GPs and individual patient interview. RESULTS: The mean age at diagnosis was 28.5 ± 7 years. Initial pathology included non-seminoma 62.8 %, seminoma 6.4 % and combined 19.2 %. All patients underwent pre-operative chemotherapy. The resection template utilised was bilateral infra-hilar in 29.5 %, unilateral infra-hilar in 46.2 % and supra-hilar in 20.5 %. Complete abdominal remission was achieved in all but one patient. Additional procedures were required in 38.5 % of patients (n = 30). Clavien Dindo grade three or four complications were seen in 8.9 %, including five patients who required early reoperation. Histology of RPLND specimen showed mature teratoma (41 %) and active cancer (11.5 %). Follow-up data were available for 66 patients (85 %). Median follow-up was 101 (11-207) months. Nine patients relapsed with median time to relapse 15 (8-60) months. Overall 5-year survival rate was 95.2 % (four deaths). CONCLUSION: In this relatively small series due to small population and low disease incidence, we have shown acceptable peri-operative course, morbidity and oncological outcomes with PC-RPLND compared to major international centres.
Authors: Andrew S Flum; Laurie Bachrach; Borko D Jovanovic; Irene B Helenowski; Sarah C Flury; Joshua J Meeks Journal: Urology Date: 2014-10-11 Impact factor: 2.649
Authors: Andrew J Stephenson; George J Bosl; Robert J Motzer; Michael W Kattan; Jason Stasi; Dean F Bajorin; Joel Sheinfeld Journal: J Clin Oncol Date: 2005-04-20 Impact factor: 44.544
Authors: M E Gels; A P Nijboer; H J Hoekstra; D T Sleijfer; W M Molenaar; J T Plukker; J H Droste; H Schraffordt Koops Journal: Br J Urol Date: 1997-02
Authors: E W Steyerberg; A Gerl; S D Fossá; D T Sleijfer; R de Wit; W J Kirkels; N Schmeller; C Clemm; J D Habbema; H J Keizer Journal: J Clin Oncol Date: 1998-01 Impact factor: 44.544
Authors: Christian Guido Ruf; Simon Krampe; Cord Matthies; Petra Anheuser; Tim Nestler; Jörg Simon; Hendrik Isbarn; Klaus Peter Dieckmann Journal: World J Surg Oncol Date: 2020-09-24 Impact factor: 2.754
Authors: Joost M Blok; Richard P Meijer; Henk G van der Poel; Axel Bex; Jeanette van Vooren; Japke J van Urk; Simon Horenblas; J L H Ruud Bosch Journal: World J Urol Date: 2020-05-05 Impact factor: 4.226